Back to Journals » Journal of Hepatocellular Carcinoma » Volume 6

Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

Authors Kastenhuber ER, Craig J, Ramsey J, Sullivan KM, Sage J, de Oliveira S, Riehle KJ, Scott JD, Gordan JD, Bardeesy N, Abou-Alfa GK

Received 15 November 2018

Accepted for publication 18 December 2018

Published 31 January 2019 Volume 2019:6 Pages 41—48


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmed Kaseb

Edward R Kastenhuber,1,2 John Craig,3 Jon Ramsey,4 Kevin M Sullivan,5 Julien Sage,6,7 Sofia de Oliveira,8 Kimberly J Riehle,5 John D Scott,5 John D Gordan,9 Nabeel Bardeesy,10,11 Ghassan K Abou-Alfa1,12

1Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Fibrolamellar Cancer Foundation, Greenwich, CT, USA; 4Department of Biochemistry, University of Vermont Cancer Center, Burlington, VT, USA; 5Northwest Liver Research Program, University of Washington, Seattle, WA, USA; 6Department of Pediatrics, Stanford University, Stanford, CA, USA; 7Department of Genetics, Stanford University, Stanford, CA, USA; 8Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA; 9Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; 10Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; 11Department of Medicine, Harvard Medical School, Boston, MA, USA; 12Department of Medicine, Weill Cornell School of Medicine, New York, NY, USA

Abstract: Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.

Keywords: fibrolamellar carcinoma, liver cancer, adolescent, young adult, fusion oncogene, cyclic AMP-dependent protein kinase catalytic subunit, heat shock protein 40

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]